Plus our top stories of the week //

This Week

Apr 11, 2025

NIH blocks researchers in China, Russia and other countries from multiple databases


Judge permanently blocks NIH grant caps, prompting HHS appeal


Eli Lilly CEO on Trump's tariffs: 'It'll be hard to come back from here'


As Trump threatens tariffs on drugs, industry warns EU of $100B-plus pharma exodus to US


‘A slow-moving catastrophe': FDA cuts are like firing all hospital staff except doctors, Janet Woodcock says


German research institute launches program to match threatened NIH grants with pharma funders

 

Featured

NIH blocks researchers in China, Russia and other countries from multiple databases

The Trump administration has blocked access to multiple data repositories maintained by the National Institutes of Health for researchers in several countries, including a cancer statistics database used regularly by scientists in China.
 

Top Stories

Judge permanently blocks NIH grant caps, prompting HHS appeal

On Monday, a federal judge permanently blocked the National Institutes of Health from implementing indirect cost caps on research grants. The NIH is now appealing.

Eli Lilly CEO on Trump's tariffs: 'It'll be hard to come back from here'

President Donald Trump’s announcement on Wednesday that pharmaceuticals imported to the U.S. would be exempt from tariff payments brought a sigh of relief from major drugmakers. But at the same time, industry leaders are bracing for the news that they think is inevitable given Trump’s declaration in February to impose “25% or higher” levies on imported drugs.

As Trump threatens tariffs on drugs, industry warns EU of $100B-plus pharma exodus to US

Although President Trump’s “Liberation Day” tariffs have spared pharmaceuticals, potential drug-specific import levies remain a sword of Damocles creating anxiety among biopharma companies. Some industry leaders now fear that more than $100 billion in investments could leave the European Union.

'A slow-moving catastrophe': FDA cuts are like firing all hospital staff except doctors, Janet Woodcock says

As President Donald Trump’s massive overhaul of federal agencies continues, several former FDA officials spoke about the potential ramifications for drug reviews and provided a look inside current FDA conditions.

German research institute launches program to match threatened NIH grants with pharma funders

As scientists across the U.S. face increasing uncertainty due to funding freezes and mass layoffs at health agencies, German research institute BioMed X is stepping in to offer a lifeline. The institute has opened a matchmaking program to align threatened NIH grants with potential new funders from the pharmaceutical industry.

FDA staff cuts could disrupt drug reviews, putting agency's critical funding programs at risk: reports

Massive cuts at the FDA have hit staff tied to drug reviews and user fees, putting future approvals in jeopardy, according to multiple reports.

CDMO AmplifyBio closes doors amid tough market for early-stage cell and gene therapy development

On the heels of a recent cost-cutting drive that severed much of AmplifyBio’s R&D capacity, the Ohio-based contract manufacturing and research hybrid has hung up its hat for good. The company attributed the decision to a downturn in the market for early-stage development of cell and gene therapies, which it said stymied its ability to grow.

PacBio to cut headcount, costs in face of tariff headwinds

Looking to get its earnings out early, PacBio posted preliminary revenue estimates this week ahead of its full quarterly report scheduled for May 8.

'SNL' star Kenan Thompson serves up a new campaign for Phathom's Voquezna

Funnyman Kenan Thompson is opening up about the not-so-funny experience of living with gastroesophageal reflux disease.
 
Fierce podcasts

Don’t miss an episode

How Oura is making the jump from consumer wellness to healthcare

This week on "Podnosis," Senior Writer Paige Minemyer chats with Jason Oberfest, vice president of healthcare at Oura, to discuss how the company is approaching its push into healthcare.
 

Resources

eBook

Through a CRO's perspective: Innovative, Agile Solutions In Vaccine Efficacy Testing

Typical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic.
Whitepaper

Protect Your Trial Data: Endpoint, Imaging, and Safety Review

Avoid costly mistakes and ensure your clinical development program meets the highest standards by reading WCG’s whitepaper on Imaging Core Labs, Endpoint Adjudication Committees (EAC), and other safety reviews.
Research

Best Practice Customer-Facing Organization Study Report

We interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned.
 

Upcoming Fierce Events

3-10
Mar-Apr
Accepting Nominations Now
3-10
Mar-Apr
Accepting Nominations Now
29-1
Apr-May
San Diego, CA
7-9
May
Free Virtual Event
14
May
Free Virtual Event

View all events